Mani Foroohar, M.D.

Mani Foroohar, M.D., is a Senior Research Analyst at Leerink Partners covering Genetic Medicines.

Prior to joining the Firm in 2013, Dr. Foroohar was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors at Aptigon Capital, a Citadel Company. Prior to that, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Dr. Foroohar co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.

Dr. Foroohar earned a B.S. from UCLA, an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, and an MBA from Columbia.